Albumin-derived immunosuppressive neo-structure P3028 (P3028)

Albumin-derived immunosuppressive neo-structure P3028 is a specific peptide or conformational variant generated through the proteolytic degradation or denaturation of serum albumin [1, 2]. It functions as a potent physiological immunosuppressor by binding to and blocking critical immune cell receptors, specifically Lymphocyte Function-associated Antigen 1 (LFA-1) and the IL-2 receptor alpha chain (CD25) [1, 3]. This interaction inhibits essential immune processes, including lymphocyte proliferation, recruitment to tumors, and natural killer (NK) cell cytotoxicity [1, 4]. P3028 is frequently expressed in the microenvironment of various solid tumors, such as melanoma, breast, and colon cancer, where it contributes to immune evasion and the development of 'immune-excluded' or 'desert' phenotypes [4, 8]. By sequestering or blocking LFA-1, P3028 prevents the successful recruitment and activation of T-cells within the tumor lesion [4, 15]. Therapeutic strategies targeting P3028, such as the complementary peptide P28R or specific anti-P3028 antibodies, aim to neutralize this neo-structure to reverse tumor-mediated immunosuppression and enhance anti-tumor immune responses [2, 8].

Other names

P3028 structureP3028 sequenceImmunosuppressive peptide P3028Albumin neo-structure P3028

P3028 acts as a ligand that binds to and blocks LFA-1 and CD25 receptors on immune cells; drugs targeting P3028, such as P28R or specific antibodies, bind to the P3028 neo-structure to prevent its interaction with these receptors, thereby restoring immune cell proliferation, migration, and cytotoxicity [1, 2, 3].